SCHEMBL19002500

SCHEMBL19002500

CCCC(=O)NCc1ccc(O)nc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.51
CYP2C19 P33261 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
FAAH O00519 2/20 0.50
HPGD P15428 4/20 0.48
ALDH1A1 P00352 1/20 0.48
TRPV1 Q8NER1 1/20 0.47
KDM4E B2RXH2 1/20 0.46
MEN1 O00255 1/20 0.46
GAA P10253 1/20 0.46
ALOX15 P16050 1/20 0.46
CASP1 P29466 1/20 0.46
KMT2A Q03164 1/20 0.46
HSD17B10 Q99714 1/20 0.46
CNR1 P21554 1/20 0.46
CNR2 P34972 1/20 0.46
HDAC3 O15379 2/20 0.44
HDAC4 P56524 2/20 0.44
HDAC1 Q13547 2/20 0.44
HDAC7 Q8WUI4 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19002492 0.81 MLLT1 (0.51) CYP3A4CYP2C19L3MBTL1FAAHKDM4E
SCHEMBL3604597 0.80 KMT2A (0.51) HPGDALDH1A1KDM4EKMT2AHSD17B10
SCHEMBL19002501 0.80 HPGD (0.59) FAAHHPGDALDH1A1HDAC3HDAC8
SCHEMBL21740798 0.80 HPGD (0.44) FAAHHPGDALDH1A1TRPV1MEN1
SCHEMBL12992173 0.78 CYP3A4 (0.68) CYP3A4CYP2C19L3MBTL1HPGDALDH1A1
SCHEMBL3600145 0.78 TSHR (0.53) CYP3A4CYP2C19L3MBTL1FAAHHPGD
SCHEMBL19002537 0.77 CYP3A4 (0.54) CYP3A4CYP2C19L3MBTL1HPGDALDH1A1
SCHEMBL18134836 0.76 CYP3A4 (0.65) CYP3A4CYP2C19L3MBTL1HPGDALDH1A1
SCHEMBL14753611 0.76 CYP3A4 (0.56) CYP3A4CYP2C19L3MBTL1FAAHHPGD
SCHEMBL2433131 0.75 MAPT (0.75) CYP3A4CYP2C19L3MBTL1FAAHHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170174699-A1 COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE SHY Therapeutics LLC 2017-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170174699-A1 COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE MAPK6, MAP3K6, MAPK4 CYP3A4 4589/4885CYP2C19 4701/4885L3MBTL1 4204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.